Integrating psychedelic medicine into mainstream mental healthcare.
We are at a crisis point
in mental health provision.
Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.
Awakn Life Sciences is a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions.
We are creating a paradigm shift in psychiatry by integrating psychedelic medicine into mainstream mental healthcare with a strategic focus on the treatment of Addiction, Anxiety, Depression and PTSD across three business divisions of Research, Clinics and Platforms.
We have a dual strategic focus of developing and commercialising psychedelic intellectual property focused on treating addiction, and treating Addiction, Anxiety, Depression, and PTSD through a chain of medical psychedelic clinics.
Our goals are to be a global leader in psychedelic clinical research for treatment of addiction, to operate the UK and EU’s leading chain of medical psychedelic clinics, and to drive lasting systemic change for patients and society through our Psychedelic Healthcare Services Platform.
The leading scientific and medical team in the industry
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Prof. Matt Johnson, Dr. Michael Mithoefer, and Ann Mithoefer
Global research leaders in psychedelic treatments
Dr. Ben Sessa has led the world’s only MDMA and AUD study (BIMA) and Prof. Celia Morgan has led the world’s leading Ketamine AUD study (KARE)
Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinical trials
Clear IP development pathway
• Phase II trial for MDMA and AUD starting in 2021
• Patents filed for psychedelic methods of treatment for AUD
Scalable Revenue Streams
• Clinic revenue starting in Q1 2021
• Licensed Methods of Treatment 2022 onwards
Significant first mover advantage in UK and EU
400m people and US$19trn GDP
Our business consistent of three related and compilatory divisions: Research, Clinics, and Platforms.
Our team has led clinical trials and research that have defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).
We have a portfolio of clinical research and trials planned and initiated focused on treating addiction.
We utilise the effects of the acute drug state induced by psychedelics alongside a course of psychotherapy to treat a range of mental health issues including Addiction, Anxiety, Depression, and PTSD.
• Bristol Q1 2021
• London & Manchester 2021
• Edinburgh, Brighton, Birmingham 2022
• EU 2023+
We are driving lasting systemic change for patients and society
• Data & Analytics
Scientific Advisory Team
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry
Awakn Appoints James Collins as Chief Operating Officer
Awakn Strengthens Scientific Leadership Team
Awakn Appoints PRA to Conduct Phase II Study of MDMA
Prof. Celia Morgan of Exeter University joins Awakn
Dr. Michael & Ann Mithoefer of MAPS join Awakn